FDAnews Device Daily Bulletin

Should Pulses Race for Medtronic?

Aug. 29, 2012
It’s ironic that keeping hearts beating at a steady pace represents more than half of medical device maker Medtronic’s business, given its stock price has dropped nearly 22% over the last five years. Not even a first quarter FY2013 earnings release showing net income growth of 5% over the previous year’s first quarter gave it much of a jump. (Unless otherwise noted, results used in this article cite Medtronic’s “constant currency basis” for clearer year-to-year comparisons.)